Study of a new drug for recurrent high-grade meningioma
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a new drug, SYHA1813, for people whose high-grade meningioma has come back or gotten worse after standard treatments like surgery and radiation. The goal is to see if this drug can help control the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed diagnosis of a grade 2 or 3 meningioma that has progressed or returned.
- You have already had surgery and radiation therapy.
- You have at least one measurable tumor in the brain that can be seen on an MRI.
- You are able to care for yourself (KPS score of 60 or higher) and are expected to live at least 3 more months.
- You agree to use reliable birth control during the study and for 3 months after treatment ends.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, SYHA1813, for people with a type of brain tumor called high-grade meningioma that has come back or gotten worse. The goal is to see if the drug can help control the tumor and improve outcomes.
This trial tests an experimental cell therapy (MT027) for people with high-grade brain tumors that have come back or stopped responding to treatment. It targets a protein called B7-H3 found on tumor cells, aiming to attack the cancer.
This trial studies NEO100, a treatment for adults and children (age 12+) with Grade II or III meningioma that has come back or kept growing after surgery and radiation. It may help shrink tumors or slow growth when standard options have not worked well enough.
This study tests a new drug called JZP3507 for people with meningioma (a type of brain tumor, grades 2 or 3) that has come back or grown despite previous treatment. The goal is to see if this medication can slow or shrink the tumor.
This trial tests a radioactive drug called 177Lu-DOTATATE for people with recurrent meningioma (a type of brain tumor) that has grown after surgery and radiation. The drug targets a protein on the tumor cells and delivers radiation directly to them.
This trial tests an experimental drug called HX301 for people with high-grade gliomas (fast-growing brain tumors). It is for patients whose tumor has come back after temozolomide chemo, or for those with newly diagnosed glioblastoma that has been surgically removed. The study aims to see if HX301 can help control the tumor.
Hear when a new High Grade Meningioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.